Channel Medsystems, a women’s health medical device company, has announced it has raised $14.1 million in new funding from investors. This significant capital infusion is set to bolster the continued development and commercialization efforts for its flagship product, the Cerene® Endometrial Cryotherapy device.
The Cerene device offers an innovative in-office treatment designed to safely and effectively reduce heavy menstrual bleeding and dysmenorrhea. A key aspect of its design is the preservation of access to the uterine cavity for future diagnostic evaluations, a feature that aligns with modern patient care standards. The treatment itself is characterized by a well-tolerated, anesthesia-free, and incision-less experience, reflecting Channel Medsystems' commitment to patient comfort and convenience.
This funding round underscores investor confidence in Channel Medsystems' technology and its potential to address critical needs in women's healthcare. The capital will be strategically deployed to accelerate growth initiatives, expand the market reach for the Cerene® device, and further enhance the company's operational capabilities. Under the leadership of President & CEO Nelson Whistance, Channel Medsystems is dedicated to delivering innovative, easy-to-use technologies that elevate patient comfort and improve clinical outcomes.
The company's overarching goal is to leverage this investment to broaden access to high-quality care for women globally. This funding positions Channel Medsystems to scale its operations and continue its mission of advancing patient-centered solutions in women's health.
